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for diagnosing mastocytosis are not met. A working confer-
ence was organized in 2010 with the aim to define criteria for 
diagnosing MCA and related disorders, and to propose a 
global unifying classification of all MC disorders and patho-
logic MC reactions. This classification includes three types of 
‘MCA syndromes’ (MCASs), namely primary MCAS, second-
ary MCAS and idiopathic MCAS. MCA is now defined by ro-
bust and generally applicable criteria, including (1) typical 
clinical symptoms, (2) a substantial transient increase in se-
rum total tryptase level or an increase in other MC-derived 
mediators, such as histamine or prostaglandin D 2 , or their 
urinary metabolites, and (3) a response of clinical symptoms 
to agents that attenuate the production or activities of MC 
mediators. These criteria should assist in the identification 
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 Abstract 
 Activation of tissue mast cells (MCs) and their abnormal 
growth and accumulation in various organs are typically 
found in primary MC disorders also referred to as mastocy-
tosis. However, increasing numbers of patients are now be-
ing informed that their clinical findings are due to MC activa-
tion (MCA) that is neither associated with mastocytosis nor 
with a defined allergic or inflammatory reaction. In other pa-
tients with MCA, MCs appear to be clonal cells, but criteria 
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and diagnosis of patients with MCAS, and in avoiding misdi-
agnoses or overinterpretation of clinical symptoms in daily 
practice. Moreover, the MCAS concept should stimulate re-
search in order to identify and exploit new molecular mech-
anisms and therapeutic targets. 
 Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Mast cells (MCs) are effector cells of allergic and other 
inflammatory reactions  [1–3] . These cells originate from 
multilineage hematopoietic progenitors that migrate to 
tissues and organs where they mature and ultimately re-
side  [2] . MCs are well known as a source of various proin-
flammatory mediators ( table 1 ) and express the high-af-
finity IgE receptor Fc  RI  [1–3] . Once activated by an al-
lergen that aggregates IgE and Fc  RI complexes or through 
a number of other receptor- or non-receptor-mediated 
stimuli, MCs release and generate mediators that contrib-
ute to the clinical features of anaphylaxis. Clinical symp-
toms caused by MC activation (MCA) are among the most 
frequent patient complaints. Signs and symptoms range 
from nausea to abdominal cramping and diarrhea, from 
mild pruritus to anaphylaxis and life-threatening hypo-
tension, and from tachycardia or unexplained arrhyth-
mias to neurologic or even psychiatric symptoms  [2, 4–7] . 
The variability of symptoms may be explained in part by 
MC heterogeneity at involved organ sites, the diversity of 
the MC-derived mediators involved ( table 1 ), the distribu-
tion and characteristics of triggering stimuli, local and 
organ-specific factors, by comorbidities, and by the mag-
nitude of the release reaction  [6–11] . Symptoms may be 
both acute and chronic  [6–13] . An underlying allergic dis-
order is found in many cases  [12–14] . Other underlying 
disorders, such as autoimmune disorders, chro nic urti-
caria or  systemic mastocytosis (SM), are less common 
 [12–16] . However, in patients mounting severe anaphylac-
tic reactions to hymenoptera venom both in the absence 
or presence of specific IgE, an underlying SM may be de-
tected  [12–20] . These patients may also suffer from ‘unex-
plained’ osteoporosis and/or gastrointestinal symptoms 
 [17, 18] . Other patients have similar symptoms without 
involvement of the MC lineage, which is important be-
cause other underlying disorders that can mimic MCA 
have to be considered and excluded before establishing the 
diagnostic checkpoint (prefinal diagnosis) of MCA.
 Although MCA appears to be increasingly important in 
adults and children, only a few robust parameters suffi-
cient for the documentation of such events by an objective 
approach are available, and only a few are useful for the 
formulation of criteria for diagnosing MCA (‘MCA crite-
ria’ for short) and disease classification  [21] . The current 
article provides a summary of consensus statements on 
MCA, MCA syndrome (MCAS), and diagnostic parame-
ters by the participants of the consensus conference, to-
gether with proposed criteria and a proposed global clas-
sification of MC disorders and pathologic MC reactions.
 Project Description, Methods and Evaluation of 
Consensus Level 
 In order to discuss issues raised in the community re-
garding MCA and to propose criteria and definitions, a 
Working Conference was organized in September 2010. 
Participating faculty members (hereinafter called ‘the 
members’) discussed current and novel diagnostic pro-
cedures, markers, criteria and algorithms in premeeting 
Table 1.  MC-derived mediators considered to contribute substan-
tially to the clinical symptoms and manifestations of MCA
Mediator Symptom(s)/sign(s) Consensus 
level1
Histamine headache, hypotension, urticaria 
with or without angioedema, 
pruritus, diarrhea
95%
PGD2 mucus secretion, broncho-
constriction, vascular instability
95%
PAF2 abdominal cramping, pulmonary 
edema, urticaria, bronchocon-
striction, hypotension, arrythmia
90%
Proinflammatory
cytokines
local inflammation, edema 
formation, leukocyte migration
80%
LTC4 and LTD4 mucus secretion, edema 
formation, vascular instability
80%
Chemokines acute inflammation and leukocyte 
recruitment, leukocyte migration
70%
Tryptase endothelial activation with con-
secutive inflammatory reactions
65%
P AF = Platelet-activating factor; LT = leukotriene. 
1 Percentage of members agreeing that these mediators play a 
predominant role in clinical signs and symptoms recorded in pa-
tients with MCA.
2 Evidence for a role of platelet-activating factor as a potential 
mediator of urticaria stems primarily from data obtained from 
healthy volunteers and in vitro studies.
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online discussions between September 2009 and Septem-
ber 2010. All members actively joined and contributed to 
pre- and postconference discussions and consensus ses-
sions. The conclusions were formulated into consensus 
statements, the level of consensus being defined as per-
cent agreement, i.e. the percentage of members agreeing 
with a given statement.
 The members also set up a pilot project to explore
patients’ opinions. Patients and patients’ organizations 
(mastocytosis) from the EU and US were invited to con-
tribute by providing their opinion by answering ques-
tionnaires. Each group was coordinated by representa-
tives of the patients’ organizations and guided by mem-
bers of the consensus consortium (C.A. and P.V.). The 
purpose of this effort was to learn about unknown or 
poorly recognized problems and concerns in the patient 
community, unmet needs, and to collect specific major 
suggestions.
 Definition and Proposed MCA Criteria  
 The members agreed (unanimously) that it is of impor-
tance to define MCA using accepted, objective, easily 
measurable, and commonly applicable parameters and 
criteria. After extensive discussions, the following criteria 
were regarded as indicative of systemic MCA: (1) typical 
clinical signs and symptoms, (2) substantial and transient 
increase in an MC-derived mediator in biological fluids 
[preferred: serum total tryptase, but also his tamine/hista-
mine metabolites and prostaglandin D 2 (PGD 2 )/PGD 2 
urinary metabolites] during or shortly after the acute 
event compared to a baseline level recorded either before 
the acute event or at least 24 h after all clinical signs and 
symptoms of the event have completely resolved, and (3) 
an objective major response of clinical symptoms to agents 
that attenuate the production or activity of MC-derived 
mediators ( table 2 ). All three criteria should be met to at-
tribute a clinical condition to systemic MCA. However, in 
some circumstances, a patient may not respond to a drug 
and may even require intensive care and epinephrine ad-
ministration. In such a patient, the condition may still be 
considered as MCA if typical symptoms (1) and an in-
crease in MC mediators (2) are present, and a primary 
underlying MC disease (e.g. SM) or an underlying IgE-
mediated disease (e.g. allergy) is known. If this is not the 
case, other explanations for the symptoms must be ruled 
out. In addition, the possibility of local MCA has to be 
considered. The criteria for systemic MCA are specified 
in more detail in the following three paragraphs.
 Clinical Symptoms 
 A number of clinical symptoms are suggestive of sys-
temic MCA, including acute urticaria (hives), flushing, 
pruritus, headache, abdominal cramping, diarrhea, vom-
iting, respiratory symptoms and hypotension ( table  3 ), 
some of which, such as urticaria, being more suggestive 
than others. When two or more organ systems exhibit 
these signs or symptoms in parallel, require therapy and 
are recurrent or even permanent, the likelihood of sys-
temic MCA increases. However, the members also agreed 
(100%) that none of these symptoms per se is specific for 
MCA and can thus only count as MCA criteria in the con-
text of the other two MCA criteria, i.e. when MC involve-
ment has been documented. Nevertheless, in an emergent 
situation where only signs and symptoms are available in 
Table 2.  Criteria for the diagnosis of MCA
Typical clinical symptoms (see table 3)
Increase in serum total tryptase by at least 20% above baseline 
plus 2 ng/ml during or within 4 h after a symptomatic period
Response of clinical symptoms to histamine receptor1 blockers or 
‘MC-targeting’ agents, e.g. cromolyn
1  Histamine receptor blockers: HR1 +/– HR2 inverse agonists.
Table 3.  Symptoms considered typical for MCA by the members
Symptom(s) Consensus level
Flushing 95%
Pruritus 90%
Urticaria 85%
Angioedema 75%
Nasal congestion 90%
Nasal pruritus 90%
Wheezing 70%
Throat swelling 85%
Headache 90%
Hypotension 95%
Diarrhea 90%
  In order to count as cocriterion of MCA, these symptoms need 
to be recurrent or permanent, cannot be explained by other 
known disorders/conditions (other than MCA), and require a 
therapeutic intervention. Moreover, apart from these symptoms, 
additional clinical and laboratory criteria have to be fulfilled for 
the condition/reaction to be considered as MCA.
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real time, a presumptive clinical diagnosis can be made 
and potentially life-saving treatment initiated without 
asking for further criteria.  Table 3 summarizes signs and 
symptoms the members regarded as suggestive of MCA 
and thus applicable as evaluation criteria of these pa-
tients. In MCA, these clinical features are considered to 
be induced by MC-derived mediators like histamine, leu-
kotriene C 4 , or PGD 2 . However, some of these mediators 
can also be released by basophils or both cell types. Oth-
er mediators like tryptase are preferentially produced in 
great abundance by MCs and thus are useful as diagnos-
tic biomarkers.
 Increase in Serum Tryptase Levels 
 After careful consideration, the members defined what 
the minimal increase in serum total tryptase above base-
line in a given patient should be to be accepted as evidence 
for systemic MCA. The generally available test (fluoroim-
mune enzyme assay, Phadia) is robust and provides high-
ly reproducible results (even at low levels) in most patients 
 [22, 23] . It is important to state that an elevated basal 
tryptase level per se is not indicative of MCA and a normal 
basal tryptase level does not exclude MCA. Another im-
portant aspect is that in primary MC disease (mastocyto-
sis), basal levels of total tryptase are usually elevated, one 
of the minor WHO criteria for SM being a basal level of 
tryptase  6 20 ng/ml  [23, 24] . It is also noteworthy that the 
rise in serum tryptase during an anaphylactic event may 
peak 15–60 min after the onset of symptoms and then de-
cline with a half-life of about 2 h. As a consequence, the 
magnitude of MC degranulation (and the severity of ana-
phylaxis) will in part determine for how long serum tryp-
tase levels will remain elevated. Thus, the timing of sam-
ple collections and the severity of the clinical event should 
be considered when interpreting tryptase levels  [23, 24] . 
Similar considerations apply to other biomarkers of MCA. 
After extensive discussion and review of key data (pub-
lished and presented at the conference), the members 
agreed (80%) that the acute serum total tryptase level 
should be at least 20% plus 2 ng/ml over the baseline level 
(of tryptase) to be indicative of MCA and thus meet this 
MCAS criterion ( table 3 ). For example, if a patient has a 
basal serum tryptase level of 10 ng/ml, the acute level 
should be  1 14 ng/ml (0.2 ! 10 + 10 + 2 ng/ml) to count 
as an MCA criterion. Although this approach seems ro-
bust, more research and prospective clinical investiga-
tions are required to validate this MCA criterion in vari-
ous clinical situations. When applying this criterion, it is 
also important to measure the basal serum tryptase level 
at least 24 h after complete resolution of all signs and 
symptoms in order to (a) confirm the transient nature of 
the reaction and (b) reveal or exclude an elevated baseline 
level of tryptase ( 1 20 ng/ml) which is highly suggestive of 
SM, even in the absence of cutaneous mastocytosis (CM), 
and would therefore prompt further investigation.
 The members also discussed whether other mediators 
should be considered in the evaluation of MCA. Hista-
mine and PGD 2 are also released from MCs during MCA, 
and may serve as biomarkers of MCA  [4, 5] . However, 
histamine lacks specificity, and both lack sensitivity and 
have preanalytical caveats  [25] . Therefore, the members 
agreed that tryptase for now remains the preferred mark-
er for the documentation of MCA. However, the members 
agreed that other parameters should be examined as 
available, and that such additional tests could be helpful 
when the tryptase test is either not available or provides 
an inconclusive result (e.g. only a slight increase during 
suspected MCA). Of these alternative biomarkers, the 
preferred ones are 24-hour urinary histamine metabo-
lites, and 24-hour urinary levels of PGD 2 or its metabolite 
11  -PGF 2    [26–30] . With regard to histamine, a caveat
is that basophils also produce and store this mediator, 
and secrete it during anaphylactic reactions. By contrast, 
PGD 2 is not produced by basophils  [31] . An unresolved 
question is what minimal increase in histamine or PGD 2 , 
or what increase in their metabolites would be required 
to be indicative of MCA. Again, more research and clini-
cal validation of markers are required before definitive 
recommendations can be provided in this regard. Alto-
gether, there is a need to further validate available bio-
markers of MCA and to develop additional objective and 
reproducible measures for the diagnosis of MCA.
 Response to Therapy 
 A major response of typical clinical symptoms to
antimediator-type pharmacological agents should be
regarded as highly suggestive of MCA. The members 
agreed that a response to therapy with histamine recep-
tor ‘blockers’ (inverse agonists) should be taken as a di-
agnostic criterion. Complete response to other drugs, 
such as glu cocorticosteroids, cromolyn, cyclooxygenase 
inhibitors, leukotriene receptor blockers, 5-lipoxygenase 
inhibitors, or antagonists of certain cytokines, may also 
be regarded as indirect evidence of MCA. However, 
many other cell types (apart from MCs) may also be in-
fluenced by these drugs, so that a response to such agents 
should be regarded as supportive but nonspecific, espe-
cially if the patient is resistant to histamine receptor 
blockers. In patients with typical symptoms, the re-
sponse to antimediator-type drugs should count as an 
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MCA criterion when a complete or major (long-lasting) 
resolution of symptoms according to published criteria 
 [18] has been documented.
 Classification of MCAS 
 The members agreed that the diagnostic algorithm 
proposed should include systemic MCA as a prediagnos-
tic checkpoint, but not as a final diagnosis ( fig. 1 ). The 
group agreed that, after reaching this checkpoint, subse-
quent studies should assess whether the patient is suffer-
ing from (1) a monoclonal MC disorder (primary MCAS), 
(2) allergy or another underlying disease causing MCA 
(secondary MCAS), or (3) idiopathic MCAS (no MC clon-
ality and no MCA trigger identified) ( fig. 1 ,  table 4 ). In 
some patients, both (1) and (2) will apply, and (2) and (3) 
may sequentially occur in the same patient  [13–15, 18–
26] . In other words, a primary MC disorder does not ex-
clude the presence of a coexisting allergy and vice versa. 
Typical clinical symptoms + transient increase in serum
tryptase levels or transient increase of another established
MC mediator + response to anti-mediator drugs
Type I allergy of
another underlying
disease leading to MCA
No allergy, no other
underlying disease, no
monoclonal MCs and no
MIS detected
Monoclonal MCs
(KIT D816V or other
 KIT exon 17 mutations)
MCA
Primary 
MCAS
Secondary
MCAS
Idiopathic
MCAS
3 minor or 1 major +
1 minor SM criteria
1 or 2 minor and no
major SM criteria
No MISSMSY
CMSY
(Mono)clonal
MCAS
MIS criteria
 Fig. 1. Diagnostic algorithm in patients with suspected MCA
disorder. In a first step, the clinical checkpoint ‘MCA’ has to
be established by MCA criteria. Then, the patient is examined for 
signs and symptoms of a clonal MC disorder, i.e. the presence of 
(mono)clonal MCs and signs and symptoms of an underlying co-
morbidity that would explain MCA, such as an allergy or chronic 
inflammation (secondary MCA). When MC clonality is proven, 
the exact variant of mastocytosis needs to be defined. If only 1 or 
2 minor SM criteria are found and no cutaneous involvement is 
detected, the final diagnosis is (mono)clonal MCAS. Note here 
that the  KIT mutation D816V already counts as a first minor SM 
criterion. If no underlying disease is detected in a patient with 
MCA, the final diagnosis is idiopathic MCAS. In some of the pa-
tients, the evaluation will show that both a primary MCAS and 
additional secondary MCAS (e.g. mastocytosis plus IgE-depen-
dent allergy) are present (asterisk). Note that for both immuno-
phenotyping of mast cells and  KIT mutation analysis, adequate 
samples and methods sufficient for revealing defects in small cell 
numbers should be applied. With regard to  KIT mutations, both 
the classical mutant  KIT D816V, but also other  KIT mutations in 
exon 17 should count as signs of MC (mono)clonality. SM SY = SM 
with mediator-related symptoms requiring therapy, i.e. SM ac-
companied by primary MCA(S). MIS = Mastocytosis in the skin. 
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In fact, in patients developing severe anaphylactic reac-
tions, the possible coexistence of these two disorders 
must be considered. Similarly, idiopathic and secondary 
MCA episodes may occur at different time points in the 
same subject. Patients with primary MCAS can be fur-
ther divided into those with true mastocytosis (by WHO 
criteria) and those fulfilling only one or two minor SM 
criteria. The latter condition can be referred to as ‘mono-
clonal MCAS’, which seems appropriate especially if  KIT 
D816V is detected  [18, 21, 32, 33] . These latter patients 
may have a precursor or a limited form of SM, but may 
have the same risk of developing severe life-threatening 
anaphylaxis as patients with true SM. Robust criteria for 
the delineation and classification of mastocytosis, ana-
phylaxis and allergic disorders have already been pub-
lished  [18, 34–38] and should be applied in all patients 
with MCA(S).  Table 4 shows an overview of categories of 
MCAS together with related criteria.
 Proposed Global Classification of MC Disorders and 
Pathologic MC Reactions 
 The members agreed (95%) that both mastocytosis 
and MCAS should be integrated into a global classifica-
tion of MC-related disorders. Before discussing the pro-
posed classification, some fundamental aspects were 
clarified. First, there is a natural overlap between this 
global classification and other classifications in internal 
medicine, simply because MCA is associated with the 
pathogenesis of a number of recognized disorders, in-
cluding allergic diseases, mastocytosis, dermatologic con-
ditions, and autoimmune disorders. The justification
of the proposed unifying-classification approach lies in 
the definitive demonstration of involvement of the MC 
lineage, which is not provided in other classifications ex-
cept for variants of mastocytosis. Second, the global clas-
sification includes neoplastic and nonneoplastic condi-
tions, a needed extension beyond previous (WHO) clas-
sifications of MC disorders. The classification proposed 
by the members is shown in  table 5 . This classification 
includes 4 major categories: MC hyperplasia, MCAS, 
mastocytosis, and myelomastocytic-overlap conditions.
 MC Hyperplasia 
 This condition is defined by a histologically confirmed 
(local or systemic) increase in tissue MCs. MC hyperpla-
sia is reactive in most cases. Independent of the organ 
analyzed, both KIT and tryptase should be applied as im-
munohistochemical markers for evaluating MC numbers 
 [35] . In addition, multicolor flow cytometry should be 
used if possible. By definition, no KIT-activating muta-
tion, no other criterion for mastocytosis (including CD2 
or CD25 expression in MCs), and no signs of a myeloge-
nous neoplasm are found. Common causes of MC hyper-
plasia are chronic infections, cancer, lymphoproliferative 
disorders, bone marrow suppression states, autoimmune 
disorders and other chronic inflammatory reactions. In 
many cases, the KIT ligand stem cell factor may be in-
volved. In support of this conclusion, injection of recom-
binant stem cell factor is usually followed by local and 
systemic MC hyperplasia  [39, 40] . MC hyperplasia can 
occur with or without MCA, but in most cases, no con-
comitant MCAS is found.
Table 4.  Classification of MCASs
Category and variants Proposed criteria
Primary MCAS
Mastocytosis
(Mono)clonal MCAS
MCA criteria fulfilled and MC (mono)clonality proven
(CD25+ MCs and/or KIT D816V)1
Secondary MCAS
Allergy
Other underlying disorder2
MCA criteria fulfilled and criteria for the diagnosis of allergy or other diseases that can 
produce MCA fulfilled as well
Idiopathic MCAS3 MCA criteria fulfilled, but no disease that could lead to MCA diagnosed
1  CD25+ MCs plus KIT D816V detectable, or KIT D816V detectable, but MCs cannot be demonstrated to express CD25.
2 Disorders associated with MCA include autoimmune diseases, certain bacterial infections and some adverse drug reactions.
3 Idiopathic MCAS is a final diagnosis but needs an extensive workup in order to exclude all potential underlying conditions and 
disorders. Idiopathic and secondary MCA episodes may occur at different time points in the same patient. 
 Mast Cell Disorders: Global 
Classification 
Int Arch Allergy Immunol 2012;157:215–225 221
 MCA Syndromes 
 As mentioned above, MCASs are defined by the pres-
ence of MCA criteria. It is again important to emphasize 
that MCAS can occur as a manifestation of another MC 
disorder (e.g. mastocytosis: primary MCAS) or as a man-
ifestation of an IgE-dependent disease (allergy: second-
ary MCAS).
 Mastocytosis 
 In general, and as developed in previous consensus 
conferences, mastocytosis is divided into CM, SM, and 
local MC tumors (mastocytoma and MC sarcoma)  [18, 
34, 41, 42] . CM is defined by ‘mastocytosis in the skin’ 
(MIS) criteria  [18] and the absence of SM (criteria for SM 
not fulfilled). SM is defined by the presence of SM criteria 
(at least 1 major + 1 minor or 3 minor WHO criteria) and 
may present with or without skin involvement  [34] . Nev-
ertheless, CM and SM are mutually exclusive conditions 
 [34] . Both CM and SM may be further divided into sub-
variants  [18, 34] . MCA can occur in any variant of mas-
tocytosis. In such cases, the presence of MCA(S) should 
be recorded as such or by the subscript ‘SY’, for ‘symp-
toms’ (e.g. SM SY )  [18, 34] .
 Myelomastocytic Overlap Conditions 
 Although not recognized as a subvariant by the WHO, 
it is important to be aware of MC lineage involvement in 
myeloid nonMC neoplasms  [43–46] . In 30–40% of all cas-
es with acute myeloid leukemia (AML), some myeloblasts 
express tryptase (tryptase+ AML)  [45] . In some of these 
cases, myeloblasts also produce histamine  [45] . However, 
patients with tryptase+ AML usually have no signs or 
symptoms of MCA. Myelomastocytic leukemia (MML) is 
an extremely rare disease  [44, 46] . In contrast to tryptase+ 
AML, a significant number of neoplastic cells ( 6 10% in 
blood or bone marrow smears) are immature MCs  [44] . 
Similar to SM or MC leukemia (MCL), MML presents 
with an elevated basal serum tryptase level and can pre-
sent with MCA. However, in contrast to SM and MCL, the 
criteria for diagnosing SM are not fulfilled  [44, 46] . Most 
cases of MML are misdiagnosed as basophilic leukemia, 
MCL, acute promyelocytic leukemia, tryptase+ AML, or 
SM with an associated hematologic nonMC lineage dis-
ease (SM-AHNMD). Similar to MCL, the prognosis in 
MML is poor  [43, 44, 46] . As mentioned above, the basal 
serum tryptase level is elevated in MML. However, this is 
not a specific feature as leukemic blasts and (neoplastic) 
basophils also express and release tryp tase  [47, 48] .
Table 5.  Global classification of MC disorders and pathologic MC reactions
Proposed term Primary definition
Mast cell hyperplasia1 Increased numbers of nonclonal MCs, an underlying disease is usually found and no signs of 
MCA are detectable; also seen in lymphoproliferative disorders and after administration of stem 
cell factor
Mastocytosis (8MCAS) Increased numbers of (mono)clonal MCs
Systemic mastocytosis SM criteria (3 minor or 1 major + 1 minor) met (SM variants, including MCL)
Cutaneous mastocytosis MIS criteria fulfilled but SM criteria not met (CM variants)
Mastocytoma Localized, benign, presumably (mono)clonal
Mast cell sarcoma Localized, aggressive (mono)clonal MCs
Mast cell activation syndrome MCA by the criteria listed in table 2
Primary MCAS CM, SM or ‘(mono)clonal MCAS’
Secondary MCAS Atopy or other disorder associated with MCA
Idiopathic MCAS No reason for MCA found
Myelomastocytic conditions MC lineage involvement in myeloid neoplasms
Tryptase+ AML Criteria for SM or MML not met, tryptase+ blasts
Myelomastocytic leukemia2 
(8MCAS)
MC lineage involvement in MDS/AML with at least 10% of all cells being clonal MCs in bone 
marrow or/and peripheral blood smears and no evidence/criteria for SM
1  MC hyperplasia is not an intrinsic MC disorder, but is a reactive state that can be seen in a wide variety of conditions, and in many 
instances, the clinical significance and mechanisms of MC expansion remain unclear. 
2 MML has not (yet) been included in the official WHO classification, although the condition is clearly defined by criteria, can 
clearly be discriminated from MCL and is of clinical significance because of the poor prognosis of these patients (similar to MCL but 
worse than other AML and MDS because of drug resistance). MIS = Mastocytosis in the skin; MDS = myelodysplastic syndrome.
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 Impact of Pathology, Genetics and Molecular 
Markers 
 The classification proposed above is seen by the mem-
bers as a logical extension of previous proposals to clas-
sify MC disorders, including the WHO classification  [41, 
42] . However, several questions remain concerning diag-
nostic parameters and assays, and the mechanisms of 
MCA. Likewise, it remains open whether all patients with 
MCA should have a bone marrow examination to estab-
lish the MCAS variant, or only those whose basal tryptase 
level is elevated (or exceeds 20 ng/ml), or only those who 
are at risk based on the recently proposed score of the 
Spanish Network of Mastocytosis (REMA score), which 
is predictive of MC clonality and includes gender, absence 
of urticaria or angioedema, presence of syncope or pre-
syncope and tryptase levels  [13] . It also remains open 
what molecular defects and markers, apart from activat-
ing  KIT mutations at codon 816 and other activating  KIT 
exon 17 mutations  [49] , might be indicative of a prima-
ry MCAS. Recent studies have shown that a number of 
additional activating  KIT mutations may be detected in 
CM, although a clear association with the pathogenesis 
of the disease often remains uncertain (apart from  KIT 
D816V)  [50] . In addition, germline single-nucleotide 
polymorphisms and other somatic mutations may con-
tribute to MCA or may augment or counteract  KIT -de-
pendent MCA. Other single-nucleotide polymorphisms 
may contribute to the evolution (progression) of an un-
derlying MC disorder  [51, 52] .
 The members agreed that research should focus on the 
identification of such novel genetic defects and establish 
whether they are associated with the pathogenesis. Fur-
ther, the clinical impact of such lesions and their applica-
bility as criteria in the future need to be considered on
a ‘case-by-case’ basis. Other molecular parameters and 
gene array features may improve diagnostic approaches 
and assist in the delineation of SM, underlying immuno-
logic diseases and various allergic disorders presenting 
with MCA.
 Impact of the Classification on Research and 
Practice 
 The major advantage of our newly proposed criteria, 
algorithm and classification may be that misdiagnosis 
and overinterpretation of MCA in clinical practice can be 
avoided, with positive implications for patients, physi-
cians and for the health care system (including economic 
aspects). For example, patients with poorly defined symp-
toms are sometimes diagnosed with MCA without a sol-
id diagnostic basis. Such patients may suffer from an un-
related disease that is then overlooked. The members of 
the consortium considered it of utmost importance to ap-
ply solid diagnostic criteria in all such patients in order 
to avoid time- and cost-consuming evaluations and es-
tablish the correct diagnosis.
 Differential Diagnoses 
 When the criteria for MCA are not met, other underly-
ing diseases that explain symptoms should be pursued. 
This is crucial as such conditions may cause continuous 
problems or may even be life-threatening. Common con-
ditions that may be confused with MCA include cardio-
vascular disorders (e.g. in patients with hypotension and 
shock), certain endocrine disorders, diverse neoplasms, 
gastrointestinal diseases, primary skin diseases, various 
infectious diseases and neurologic or psychiatric condi-
tions. It is important to explore these alternative diagno-
ses carefully and to record all symptoms and laboratory 
parameters that may help the physician to arrive at the 
correct conclusion. Serum tryptase as well as other avail-
able MC biomarkers should be determined in these pa-
tients. If such values are normal, they should be repeated 
in the follow-up if symptoms occur. If histamine or hista-
mine metabolite levels increase during an attack, but 
tryptase levels remain consistently normal, the condition 
may be related to basophil activation or a histamine-se-
creting (carcinoid) tumor. Even in patients in whom no 
(systemic) increase in any mediator can be documented, 
the possibility remains that local tissue-based symptoms 
result from basophil activation and/or MCA within these 
tissues. However, such a scenario is unlikely to result in 
systemic symptoms, and local consequences of MC re-
lease, such as urticaria, angioedema, rhinitis and asthma, 
are obvious. Additionally, local MC degranulation within 
inflammatory reactions such as inflammatory bowel dis-
ease has been reported but should not be taken as evidence 
that the pathology is primarily MC dependent. These con-
siderations should be kept in mind when a patient has typ-
ical symptoms ( table 3 ) and is responding well to cromo-
lyn, whose cell target(s) and mechanism(s) of action are 
nonspecific  [53] . A special differential diagnosis is hista-
mine intoxication following ingestion of histamine or its 
metabolites, which may be present, for instance, in wine, 
seafood, fish or soy sauce  [54] . Another condition that has 
been reported is histamine intolerance, which has been 
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suggested to result from an abnormal histamine metabo-
lism  [55, 56] . It remains unknown whether these patients 
indeed react inappropriately to small quantities of hista-
mine or may suffer from an increased level of endogenous 
or exogenous histamine. Interestingly, some of these pa-
tients turn out to have SM when basal tryptase levels are 
measured and found to be elevated – and then, a bone 
marrow examination needs to be performed.
 Open Questions and Issues Raised by Patients 
 Although definitions and criteria for MCA and masto-
cytosis are presented within this consensus document and 
should assist in daily practice, questions remain. Like-
wise, physicians are often unsure about the diagnosis of 
SM or confuse SM with other medical disorders. In other 
cases, MCAS is diagnosed without proper examination 
and documentation. In order to explore the patients’ views 
on these questions, we completed two pilot projects with 
an identical setup, one in the US and one in the EU. In this 
project, many of the urgent issues and suggestions were 
formulated and listed by patients. The two projects were 
conducted under the guidance of members of the consen-
sus group (C.A. in the US and P.V. in the EU). The 10 top 
important proposals are listed in  table 6 . As expected for 
a rare disease, the patients’ wish is to increase the number 
of reference and referral centers and expert physicians in 
the EU and US. Other important issues to be solved by the 
community are to develop more effective therapies for the 
various categories of the disease, and to extend general 
awareness and knowledge on disease variants. Patients’ 
opinions and suggestions were presented in detail to the 
members at the consensus conference, and there was 
unanimous recognition that the academic community is 
appreciative of this initiative, and that the patients’ sug-
gestions are to be considered in forthcoming projects and 
network activities. The European Competence Network 
on Mastocytosis (ECNM)  [57] and similar initiatives in 
the US will continue to assume a leading role in efforts to 
address these issues and concerns, preferably in coopera-
tion projects and concerted actions.
 Concluding Remarks and Future Perspectives 
 The MC lineage is involved in diverse pathologic reac-
tions and medical disorders. The spectrum of related 
clinical symptoms and pathologies is broad. As a conse-
quence, disorders attributed primarily to MCA need clear 
Table 6.  Top 10 issues raised by patients in the US and EU
US EU
1. Better access to care from physicians knowledgeable
in MC disorders and more specialized centers
1. Improved knowledge of all doctors in various disciplines 
relevant to MC disorders
2. Definitions and criteria for MCAS (clonal and nonclonal 
variants)
2. ID card for all patients and countries in Europe
3. Curative rather than symptomatic therapy 3. New better therapeutic agents
4. Education and awareness of physicians and health care 
professionals in recognition of symptoms of MC disorders
4. More specialized centers in various countries in the EU
5. Practice parameters of diagnosis and therapy incorporating 
commonly available methods
5. Improved knowledge and definition of mediator-associated 
symptoms
6. Better access to and assistance in obtaining medications 6. More mastocytosis specialists
7. More recognition of gastrointestinal manifestations of MC 
diseases
7. Improved diagnostic methods
8. Better holistic care plans to address symptoms such as
anaphylaxis, fatigue, bone pain, brain fog, pain and
neuropsychiatric symptoms
8. More information to patients
9. More research into familial occurrence 9. Further development of existing classifications of MC
disorders
10. New treatment options for cutaneous disease, aggressive SM 
and MCL
10. More information to patients via commonly accessible
media
  The two reports (EU and US) were prepared independently by using documented material provided by the patients’ organizations, 
and with assistance by 2 faculty members. 
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